1、前列地爾脂微球載體注射液對(duì)老年下肢動(dòng)脈血管病變患者血小板活化功能的影響 10-09-09 16:46:00 編輯：studa20 作者：馮淑芝 孫寧 曹麗 田建立 陳珺【摘要】 目的 探討前列地爾脂微球載體注射液對(duì)老年下肢動(dòng)脈血管病變患者血小板活化功能的影響。方法 選擇老年下肢動(dòng)脈血管病變患者120例，隨機(jī)分為對(duì)照組（60例）和治療組（60例）。對(duì)照組每日給予銀杏葉提取物注射液70 mg/d溶解在250 ml生理鹽水中靜脈滴注，連續(xù)使用14 d，治療組采用前列地爾脂微球載體注射液20 g/d溶解在20ml生理鹽水中靜脈慢推，連續(xù)治療14 d，觀察兩組患者治療前后的癥狀、股動(dòng)脈、腘動(dòng)脈、脛后動(dòng)脈

2、、足背動(dòng)脈內(nèi)徑及血流量的變化，并測(cè)定血糖、血脂、肝酶、腎功能、血小板顆粒膜糖蛋白140、血小板CD62p和CD63以及前列環(huán)素、血栓素。結(jié)果 治療組治療后老年下肢動(dòng)脈血管病變患者癥狀明顯改善，股動(dòng)脈、腘動(dòng)脈、脛后動(dòng)脈、足背動(dòng)脈內(nèi)徑及血流量均有所增加，血小板膜顆粒糖蛋白140、CD62p、CD63以及前列環(huán)素、血栓素有所下降(P0.05)，其他生化指標(biāo)無(wú)明顯變化(P0.05)。結(jié)論 前列地爾脂微球載體注射液可以降低老年下肢動(dòng)脈血管病變患者血小板的活化功能，有效改善其癥狀，安全用于老年患者的治療。 【關(guān)鍵詞】 前列地爾脂微球載體注射液；老年人；下肢動(dòng)脈血管；血小板活化功能【Abstract】 Ob

3、jective To assess the infection of Liposomal prostaglandin E1 (LipoPGE1) on hematoblastic activation function with lower limb arterial blood vessel disease in geriatrics. Methods 120 patients with lower limb blood arterial vessel disease were randomly divided into control and treatment groups. Patie

4、nts in treatment group were administered with LipoPGE1 (20 g/d) for 14 days, patients in control group were administered with Ginkgo Biloba Leaf Extract (70 mg/d) for 14 days. Clinical symptom was observed, vascular diameter and blood flow velocity of femoral artery, popliteal artery, posterior tibi

5、al artery and dorsal pedal artery were evaluated by Doppler uitrasonography examination, blood glucose level, blood lipid level, peptase, renal function, granule membrane protein (GMP140), hematoblastic CD62p and CD63, 6ketoneprostacyclin(6kPGF1), thromboxane B2(TXB2) were measured pre and post trea

6、tment. Results After given LipoPGE1 post treatment, the clinical symptoms and signs had been mended in the patients with lower limb arterial blood vessel disease, vascular diameter and blood flow velocity of femoral artery, popliteal artery, posterior tibial artery and dorsal pedal artery were incre

7、ased, however, there were no significantly differences. GMP140, CD62p, CD63, 6kPGF1,TXB2 were decreased, and there were significant differences between control and treatment groups (P0.05). The other indicators did not change, there were no significant differences (P0.05). Conclusions LipoPGE1 can i

8、nhibite hematoblastic activation function, improve the symptom with lower limb arterial blood vessel disease, which is safe to senile patients. 【Key words】 Liposomal prostaglandin E1(LipoPGE1)；Geriatrics；Lower limb arterial blood vessel；Hematoblastic activation function下肢動(dòng)脈硬化是老年人常見(jiàn)的一種慢性疾病，這種疾病的血液循環(huán)中

9、處于靜息狀態(tài)的血小板在各種理化因素和生物因子的作用下活化,顆粒膜蛋白整合到活化的血小板質(zhì)膜上，參與止血、凝血、炎癥、免疫及組織的修復(fù)過(guò)程，直接或間接作用于血管壁和/或其基質(zhì)部分，引起內(nèi)皮功能紊亂，導(dǎo)致血管內(nèi)斑塊和血栓形成1。本文通過(guò)觀察應(yīng)用前列地爾脂微球載體注射液(lipoPGE1)前后老年下肢動(dòng)脈血管病變患者血漿血小板顆粒膜糖蛋白140（granule membrane protein，GMP140）、血小板CD62p和CD63以及前列環(huán)素（6ketoneprostacyclin，6kPGF1）、血栓素B（TXB2）的變化，了解其對(duì)血小板活化功能的影響。1 對(duì)象與方法1.1 研究對(duì)象 選取自

10、2006年10月2007年10月在我院干部病房住院患者120例，男89例,女31例,年齡6497(平均78.669.07歲)。所有患者均經(jīng)超聲多普勒證實(shí)存在下肢動(dòng)脈血管性病變,診斷標(biāo)準(zhǔn)參考2。排除標(biāo)準(zhǔn):合并有嚴(yán)重的心、肝、腎或血液系統(tǒng)疾病者；血壓控制不理想者；有出血傾向者；活動(dòng)性消化性潰瘍患者；青光眼患者；一個(gè)月內(nèi)曾受外傷或接受手術(shù)治療患者。1.2 實(shí)驗(yàn)方法1.3 統(tǒng)計(jì)學(xué)分析 使用SPSS11.5統(tǒng)計(jì)軟件，計(jì)量資料以xs表示，組間比較采用t檢驗(yàn)，計(jì)數(shù)資料率的比較采用2檢驗(yàn)。2 結(jié)果2.1 一般情況 治療前兩組患者的年齡、性別匹配，下肢動(dòng)脈內(nèi)徑和血流量、各項(xiàng)血液檢查指標(biāo)無(wú)明顯差異(均P0.05)，兩組具有可比性，見(jiàn)表1。2.2 兩組治療前后動(dòng)脈內(nèi)徑和血流量的變化 治療組治療后患者股動(dòng)脈、腘動(dòng)脈、脛后動(dòng)脈、足背動(dòng)脈的內(nèi)徑和血流量均較治療前有所改善，而對(duì)照組下肢動(dòng)脈血管內(nèi)徑及血流量在治療前后沒(méi)有變化，但兩組治療方法對(duì)下肢動(dòng)脈內(nèi)徑和血流量的影響無(wú)明顯差異(P0.05)，見(jiàn)表2。2.3 兩組治療前后血液檢查指標(biāo)變化 兩種治療方法對(duì)血常規(guī)、肝酶、腎功能、血糖、血脂等沒(méi)有影響